Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for LEE011

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug LEE011?

LEE011 is an investigational drug.

There have been 72 clinical trials for LEE011. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2015.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Liposarcoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and Array BioPharma.

There are thirty-seven US patents protecting this investigational drug and four hundred and eighty-two international patents.

Recent Clinical Trials for LEE011
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerNovartis PharmaceuticalsPhase 2
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesNovartis PharmaceuticalsPhase 1
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerTranslational Research in OncologyPhase 3

See all LEE011 clinical trials

Clinical Trial Summary for LEE011

Top disease conditions for LEE011
Top clinical trial sponsors for LEE011

See all LEE011 clinical trials

US Patents for LEE011

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LEE011   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
LEE011   Start Trial Ribociclib intermediate and preparation method therefor SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (Suzhou, CN)   Start Trial
LEE011   Start Trial Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer Novartis AG (Basel, CH)   Start Trial
LEE011   Start Trial Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH)   Start Trial
LEE011   Start Trial Androgen receptor mutation Novartis AG (Basel, CH)   Start Trial
LEE011   Start Trial Pharmaceutical combinations Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LEE011

Drugname Country Document Number Estimated Expiration Related US Patent
LEE011 Australia 2014348657 2033-11-13   Start Trial
LEE011 Australia 2017245411 2033-11-13   Start Trial
LEE011 Canada 2929181 2033-11-13   Start Trial
LEE011 China 105899232 2033-11-13   Start Trial
LEE011 Eurasian Patent Organization 201690987 2033-11-13   Start Trial
LEE011 European Patent Office 3068435 2033-11-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.